Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7381427 | ACLARIS | Seborrheic keratosis treatment |
Jun, 2022
(1 year, 10 months ago) | |
US10098910 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | |
US9980983 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | |
US10493103 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | |
US10729720 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | |
US9675639 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Jul, 2035
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 14, 2020 |
Market Authorisation Date: 14 December, 2017
Treatment: Treatment of seborrheic keratoses that are raised
Dosage: SOLUTION;TOPICAL